Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

Blood. 2002 Mar 15;99(6):1909-12. doi: 10.1182/blood.v99.6.1909.

Abstract

Therapy-related acute myeloid leukemia (t-AML) in most cases develops after chemotherapy of other malignancies and shows characteristic chromosome aberrations. Two general types of t-AML have previously been identified. One type is observed after therapy with alkylating agents and characteristically presents as therapy-related myelodysplasia with deletions or loss of the long arms of chromosomes 5 and 7 or loss of the whole chromosomes. The other type is observed after therapy with topoisomerase II inhibitors and characteristically presents as overt t-AML with recurrent balanced chromosome aberrations. Recent research suggests that these 2 general types of t-AML can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Antineoplastic Agents, Alkylating / adverse effects
  • Chromosome Aberrations / chemically induced
  • DNA Methylation
  • DNA Topoisomerases, Type II / adverse effects
  • Humans
  • Leukemia, Myeloid / chemically induced
  • Leukemia, Myeloid / etiology
  • Leukemia, Myeloid / genetics*
  • Mice
  • Models, Genetic
  • Myelodysplastic Syndromes / chemically induced
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / genetics*
  • Neoplasms, Second Primary / chemically induced
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / genetics*
  • Promoter Regions, Genetic

Substances

  • Antineoplastic Agents, Alkylating
  • DNA Topoisomerases, Type II